StockpollyBeta
Get App
Popularity #2,383
DRTS · NASDAQ · Biotechnology

Alpha Tau Medical (DRTS)

Develops Alpha DaRT, a localized alpha-radiation therapy for solid tumors.

$15.14
After hours−0.01 (−0.07%)
At close$15.15(−2.26%)

  1. Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More

    Seeking Alpha

  2. Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions

    GlobeNewsWireClinical

  3. Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success

    GlobeNewsWire

  4. Alpha Tau Medical (NASDAQ:DRTS) Trading 7.1% Higher – Here’s Why

    Defense World

  5. Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

    GuruFocus

  6. Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

    GlobeNewsWire

  7. Alpha Tau Medical: A Lot Of Shots On Goal

    Seeking Alpha

  8. Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

    GlobeNewsWire

  9. Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

    GlobeNewsWire

  10. Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears

    MarketBeat

  11. Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

    GlobeNewsWire

  12. Alpha Tau to Participate in May Investor Conferences

    GlobeNewsWire

  13. Alpha Tau Medical Stock Surges As Interim Brain Tumor Trial Data Sparks Rally

    Benzinga

  14. Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study

    MarketBeat

  15. Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

    GlobeNewsWire

  16. Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

    GlobeNewsWire

  17. Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona's Pancreas Institute

    GlobeNewsWire

  18. Alpha Tau Reports 100% Local Disease Control in Early Pancreatic Cancer Data as Program Gains Momentum (DRTS)

    GuruFocus

  19. Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab

    GlobeNewsWire

  20. Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies

    GlobeNewsWire